【摘要】：尋找抑郁癥患者血清中潛在生物標(biāo)志物,為抑郁癥臨床診斷及藥物作用機(jī)制研究提供依據(jù)。篩選符合納入標(biāo)準(zhǔn)的16例中重度抑郁癥患者和16例健康人分別作為疾病組和對(duì)照組,其中疾病組抑郁癥患者服用抗抑郁藥物帕羅西汀兩周。采集對(duì)照組、抑郁癥患者以及抑郁癥患者服用帕羅西汀兩周后的血清進(jìn)行1H NMR測(cè)試,采用代謝組學(xué)技術(shù)結(jié)合多元統(tǒng)計(jì)方法分析血清中內(nèi)源性代謝產(chǎn)物的變化及其規(guī)律,發(fā)現(xiàn)具有顯著性差異的代謝產(chǎn)物,結(jié)合相關(guān)代謝途徑及受試者工作曲線(ROC)分析發(fā)現(xiàn)潛在生物標(biāo)志物,并進(jìn)一步探討其與抑郁癥的相關(guān)性及應(yīng)用于臨床診斷的可靠性和可行性。抑郁癥患者血清中谷氨酸、谷氨酰胺、丙氨酸、N-乙酰糖蛋白、亮氨酸及異亮氨酸的水平顯著升高,而葡萄糖水平顯著降低(P0.05,P0.01),而帕羅西汀對(duì)丙氨酸、N-乙酰糖蛋白、異亮氨酸及葡萄糖代謝水平具有顯著的回調(diào)作用(P0.05,P0.01),并調(diào)節(jié)谷氨酸、谷氨酰胺及異亮氨酸代謝水平使其具有向正常水平恢復(fù)的趨勢(shì),因此可被確定為潛在生物標(biāo)志物。上述生物標(biāo)志物的應(yīng)用將有助于提高抑郁癥臨床診斷的客觀性和抗抑郁藥物臨床療效評(píng)價(jià)的準(zhǔn)確性。
[Abstract]:To search for the potential biomarkers in the serum of depression patients and to provide evidence for the clinical diagnosis of depression and the mechanism of drug action. Sixteen patients with moderate and severe depression and 16 healthy persons were selected as disease group and control group respectively. Patients with depression in disease group were treated with paroxetine for two weeks. The serum of control group, patients with depression and patients with depression were tested for 1H NMR after taking paroxetine for two weeks. The changes and regularity of endogenous metabolites in serum were analyzed by metabolomics technique and multivariate statistical method. The potential biomarkers were found by (ROC) analysis of related metabolic pathways and operating curves of subjects. The relationship between the metabolites and depression and the reliability and feasibility of their application in clinical diagnosis were discussed. The levels of glutamate, glutamine, alanine N-acetylglycoprotein, leucine and isoleucine in the serum of patients with depression increased significantly, while the level of glucose decreased significantly (P0.05, P0.01). The metabolic level of isoleucine and glucose has a significant correction effect (P0.05, P0.01), and regulates the metabolism of glutamate, glutamine and isoleucine, so that it has a tendency to recover to normal level, so it can be identified as a potential biomarker. The application of these biomarkers will help to improve the objectivity of clinical diagnosis of depression and the accuracy of evaluation of clinical efficacy of antidepressants.
【作者單位】： 山西大學(xué)中醫(yī)藥現(xiàn)代研究中心;山西大學(xué)化學(xué)化工學(xué)院;山西醫(yī)科大學(xué)第一醫(yī)院;
【基金】：國家自然科學(xué)基金資助項(xiàng)目(81173366;81441096)
【分類號(hào)】：R969

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 周春顏;;抑郁癥及抑郁藥物的合理應(yīng)用[J];遼寧醫(yī)學(xué)雜志;2007年03期

2 姜佐寧;;抑郁癥化學(xué)治療的進(jìn)展與現(xiàn)狀[J];北京第二醫(yī)學(xué)院學(xué)報(bào);1985年03期

3 錢連華 ,陸丙耕;新的抗抑郁藥物對(duì)抑郁癥的啟示[J];新藥與臨床;1987年02期

4 ;溴隱亭用于治療抑郁癥[J];國外醫(yī)學(xué).藥學(xué)分冊(cè);1990年02期

5 鮑仕慧;張友婷;王增壽;戴王磊;;對(duì)抑郁癥患者的藥學(xué)服務(wù)[J];中國臨床藥學(xué)雜志;2007年05期

6 夏訓(xùn)明;;美國FDA批準(zhǔn)一種治療抑郁癥新藥Viibryd[J];廣東藥學(xué)院學(xué)報(bào);2011年01期

7 ;鋰鹽對(duì)抑郁癥的療效[J];臨床精神醫(yī)學(xué)雜志;1998年02期

8 ;抗抑郁癥新藥[J];技術(shù)與市場;2005年12期

9 姜佐寧;;抑郁癥的化學(xué)治療[J];中級(jí)醫(yī)刊;1979年05期

10 劉志華;;淺析首發(fā)抑郁癥患者藥物使用情況[J];中國處方藥;2014年07期

相關(guān)會(huì)議論文 前1條

1 樊寶華;;長期血小板減少致抑郁癥一例[A];2009年浙江省醫(yī)學(xué)會(huì)精神病學(xué)學(xué)術(shù)年會(huì)暨浙江省醫(yī)師協(xié)會(huì)精神科醫(yī)師分會(huì)第二屆年會(huì)論文匯編[C];2009年

相關(guān)重要報(bào)紙文章 前2條

1 伊遙;抑郁癥新藥前景可期[N];中國醫(yī)藥報(bào);2011年

2 本報(bào)記者 李佳;解密“西汀們”的發(fā)跡史[N];醫(yī)藥經(jīng)濟(jì)報(bào);2013年

，

本文編號(hào)：2151545